Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-α-2a in patients with advanced malignancies

Investigational New Drugs

Volumn 13, Issue 4, 1995, Pages 315-320

  Wadler, Scott ^a   Haynes, Hilda ^a   Schechner, Richard ^a   Rozenblit, Alla ^a   Wiemik, Peter H ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

5 fluorouracil; biochemical modulation; hydroxyurea; interferon

Indexed keywords

FLUOROURACIL; GRANISETRON; HYDROXYUREA; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CARDIOPULMONARY ARREST; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM SEPTICUM; COLORECTAL CANCER; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; FATALITY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; NAUSEA; OUTPATIENT CARE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; DOSE RESPONSE; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; HYDROXYUREA; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0029680548     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00873137     Document Type: Article

References (26)

1. Ribonucleotide reductases: amazing and confusing
2. Assignment of the structural gene for subunit M1 of human ribonucleotide reductase to the short arm of chromosome 11
3. Cell-cycle dependent regulation of mammalian ribonucleotide reductase
4. Hydroxyurea and related compounds
5. Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation
6. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis
7. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis
8. Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea
9. Combined cytotoxic effect of low-dose 5-fluorouracil and hydroxyurea on 9L cells in vitro
10. Factors modifying cytotoxicity induced by 5-FU and hydroxyurea
11. Enhancement of antitumor activity of 5-fluorouracil by drug combinations
12. Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer
13. Clinical experience using hydroxyurea and 5-fluorouracil in hepatic metastasis from adenocarcinoma of the colon
14. Trial based on biochemical modulation of 5-fluorouracil (5FU) by daily sequential hydroxyurea (HU) in colorectal cancer
15. Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer
16. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization
17. Interaction of fluorouracil and Interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects
18. Design and conduct of clinical trials
19. Toxicity and response criteria of the Eastern Cooperative Oncology Group
20. Recognition, management, and prevention of Clostridium septicum abscess in immunosuppressed patients
21. Clostridium septicum infections and malignancy
22. Clostridium septicum bacteremia: its clinical significance
23. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy
24. Low dose hydroxyurea synergy with 5-fluorouracil by modulating ribonucleotide reductase and thymidylate synthetase expression
25. Hydroxyurea resistant human KB cells exhibit collateral sensitivity to 5-fluorouracil under low dose hydroxyurea induction